Appili Therapeutics Presents at the 10th International Tularemia Conference
September 27 2023 - 7:27AM
Business Wire
Recently announced Funding Commitment from U.S. Air Force is
expected to advance ATI-1701 Biodefense Vaccine Candidate to
IND
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the
“Company” or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases and biodefense, today announced
that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and
key members of Appili’s scientific team, will participate at the
10th International Tularemia Conference, from September 24 to 26,
2023. Dr. Gelhaus will present an update on Appili’s biodefense
vaccine program ATI-1701.
“The International Tularemia Conference is the premier tularemia
conference in the world, and we look forward to sharing the
progress we have made on ATI-1701 over the past several years and
strengthen relationships with leading tularemia clinicians and
researchers,” said Dr. Gelhaus. “We remain encouraged by recently
announced U.S. government funding commitments for ATI-1701 and look
forward to collaborating with other tularemia experts toward the
first approved vaccine for the prevention of weaponized
tularemia.”
The presentation will include an overview of ATI-1701, Appili’s
potential first-in-class vaccine candidate for the prevention of
infection with F. tularensis, the causative agent of tularemia and
a top-priority biothreat. Since it is a highly infectious pathogen
capable of causing severe illness, medical counter measures for F.
tularensis are a top biodefense priority for the United States and
governments around the world.
In May 2023, Appili announced a commitment of funding for
ATI-1701 from the U.S. Air Force (“USAFA”), who is working in
partnership with the Defense Threat Reduction Agency (“DTRA”), the
funding agency.
Presentation details are as follows:
Title: ATI-1701: A Live Attenuated Tularemia
Vaccine Based on a SCHU S4 ΔclpB Mutant Date: Thursday,
September 28 Time: 2:30 – 2:45p.m. CEST
Appili management will also be conducting in-person meetings
throughout the conference. To request a meeting, please register
for the conference here.
About ATI-1701 Appili is developing ATI-1701 as a vaccine
to combat Francisella tularensis, which is classified by the U.S.
National Institutes of Health (NIH) as a Category A pathogen, an
organism that poses the highest risk to national security and
public health. Estimated to be 1,000-fold more infectious than
anthrax, experts consider the aerosolized form to have a high
potential for use in a bioterrorism attack.
About Triennial International Tularemia Conference The
International Conferences fulfill a major purpose of the Tularemia
International Society, namely to facilitate the assembly,
acquaintance, and association of scientists engaged in tularemia
research. Tularemia meetings focus on fundamental, clinical, and
applied research regarding any aspect of Francisella tularensis.
Research uncovers not only the biology of this fascinating
bacterium, but also provides the basis for future development of
treatments, preventive interventions, and disease diagnosis.
About Appili Therapeutics Appili Therapeutics is an
infectious disease biopharmaceutical company that is purposefully
built, portfolio-driven, and people-focused to fulfill its mission
of solving life-threatening infections. By systematically
identifying urgent infections with unmet needs, Appili’s goal is to
strategically develop a pipeline of novel therapies to prevent
deaths and improve lives. The Company is currently advancing a
diverse range of anti-infectives, including a vaccine candidate to
eliminate a serious biological weapon threat, a topical
antiparasitic for the treatment of a disfiguring disease, and a
novel easy to use, liquid oral formulation targeting parasitic and
anaerobic infections. Led by a proven management team, Appili is at
the epicenter of the global fight against infection. For more
information, visit www.AppiliTherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230926093626/en/
Media: Jenna McNeil, Communications Manager Appili
Therapeutics JMcNeil@AppiliTherapeutics.com
Investor Relations: Don Cilla, President and CEO Appili
Therapeutics Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Apr 2024 to May 2024
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From May 2023 to May 2024